Marijuana use and viral suppression in persons receiving medical care for HIV-infection

References

• Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 Mar 26;338:853–860.
   Google Scholar
• Wood E, Montaner JSG, Yip B, Tyndall MW, Schechter MT, O’Shaughnessy MV, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther 2004 Apr;9:229–235.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS Lond Engl 1999 Jun 18;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Low-Beer S, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr (1999) 2000 Apr 1;23:360–361.
   Google Scholar
• Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis Off Publ Infect Dis Soc Am 2002 Apr 15;34:1115–1121.
   Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011 Aug 11;365:493–505.
   PubMed Web of Science ®Google Scholar
• Parienti J-J, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 2008 Jul 30;3:e2783.
   Web of Science ®Google Scholar
• Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav 2014 Oct 24;19:601–611.
   Google Scholar
• Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care 2013 Apr 1;25:400–414.
   Web of Science ®Google Scholar
• Gonzalez JSP, Frank J, Llabre Maria M, Durán Ron E, Antoni Michael H, Schneiderman Neil, Horne, Rob. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007 Jul;34:46–55.
   PubMed Web of Science ®Google Scholar
• Palepu A, Milloy M-J, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health Bull N Y Acad Med 2011 Jun;88:545–555.
   PubMed Web of Science ®Google Scholar
• Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addict Abingdon Engl 2008 Aug;103:1242–1257.
   PubMed Web of Science ®Google Scholar
• Newville H, Berg KM, Gonzalez JS. The interaction of active substance use, depression, and antiretroviral adherence in methadone maintenance. Int J Behav Med 2015;22:214–222.
   Google Scholar
• Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav 2013;17:142–147.
   PubMed Web of Science ®Google Scholar
• Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr (1999) 2006 Dec 1;43:411–417.
   Web of Science ®Google Scholar
• Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr (1999) 2009 Jan 1;50:93–99.
   Web of Science ®Google Scholar
• Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004 Mar 1;99:361–368.
   Web of Science ®Google Scholar
• DʼSouza G, Matson PA, Grady CD, Nahvi S, Merenstein D, Weber KM, et al. Medicinal and recreational marijuana use among HIV-infected women in the womenʼs interagency HIV study (WIHS) cohort, 1994–2010. JAIDS J Acquir Immune Defic Syndr 2012 Dec;61:618–626.
   PubMed Web of Science ®Google Scholar
• Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 1999. 2004 Jan 1;35:38–45.
   Web of Science ®Google Scholar
• Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health 2013 Aug;103:1457–1467.
   PubMed Web of Science ®Google Scholar
• Harris GE, Dupuis L, Mugford GJ, Johnston L, Haase D, Page G, et al. Patterns and correlates of cannabis use among individuals with HIV/AIDS in maritime Canada. Can J Infect Dis Med Microbiol 2014;25:e1–e7.
   PubMed Web of Science ®Google Scholar
• Ware MA, Rueda S, Singer J, Kilby D. Cannabis use by persons living with HIV/AIDS: patterns and prevalence of use. J Cannabis Ther 2003 Mar 1;3:3–15.
   Google Scholar
• Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDs. 2004 Apr;18:215–228.
   PubMed Web of Science ®Google Scholar
• Williams JC, Appelberg S, Goldberger BA, Klein TW, Sleasman JW, Goodenow MM. Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 2014 Jun;9:369–379.
   PubMed Web of Science ®Google Scholar
• Costantino CM, Gupta A, Yewdall AW, Dale BM, Devi LA, Chen BK. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PloS One 2012;7:e33961.
   PubMed Web of Science ®Google Scholar
• Molina PE, Winsauer P, Zhang P, Walker E, Birke L, Amedee A, et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses 2011 Jun;27:585–592.
   PubMed Web of Science ®Google Scholar
• Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 2013 Jun;8:608–620.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Schuster RM, Vassileva J, Martin EM. Impact of HIV and a history of marijuana dependence on procedural learning among individuals with a history of substance dependence. J Clin Exp Neuropsychol 2011 Aug;33:735–752.
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 2012 Aug 27;201206820.
   Google Scholar
• Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev 2013 Jun;23:117–137.
   PubMed Web of Science ®Google Scholar
• Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009 Oct;24:515–523.
   PubMed Web of Science ®Google Scholar
• Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran F, Marti­n-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (Oxf) [Internet]. 2010 Sep 9 [cited 2016 Mar 24]. Available at: http://jop.sagepub.com/content/early/2010/09/08/0269881110379283
   Google Scholar
• Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 2015 Mar;162:153–161.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al. Short-term effects of cannabinoids in patients with HIV-1 Infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003 Aug 19;139:258–266.
   PubMed Web of Science ®Google Scholar
• Milloy M-J, Marshall B, Kerr T, Richardson L, Hogg R, Guillemi S, et al. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. Drug Alcohol Rev 2015 Mar;34:135–140.
   PubMed Web of Science ®Google Scholar
• Thames AD, Mahmood Z, Burggren AC, Karimian A, Kuhn TP. Combined effects of HIV and marijuana use on neurocognitive functioning and immune status. AIDS Care 2016;28:628–632.
   Google Scholar
• Ghosn J, Leruez-Ville M, Blanche J, Delobelle A, Beaudoux C, Mascard L, et al. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. Clin Infect Dis Off Publ Infect Dis Soc Am 2014 Jun;58:1763–1770.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. HIV Surveillance Report, 2014 [Internet]. 2015 Nov [cited 2016 Mar 20] p. Vol 26. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/
   Google Scholar
• NORML (National Association for the Reform of Marijuana Laws). Florida Laws & Penalties. [cited 2016 Mar 14]. Available at: http://norml.org/laws/item/florida-penalties
   Google Scholar
• Frankel MR, McNaghten A, Shapiro MF, Sullivan PS, Berry SH, Johnson CH, et al. A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. Open AIDS J. 2012;6:67–76.
   PubMedGoogle Scholar
• McNaghten AD, Wolfe MI, Onorato I, Nakashima AK, Valdiserri RO, Mokotoff E, et al. Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. PLoS One 2007 Jun 20;2:e550.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch [Internet]. 2010 [cited 2015 Mar 13]. Available at: http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-publichealth-research-nonresearch.pdf
   Google Scholar
• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med 2001 Sep;16:606–613.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999 Nov 10;282:1737–1744.
   Google Scholar
• Helping patients who drink too much: a clinician’s guide [Internet]. NIAAA: National Institute of Alcohol Abuse and Alcoholism; [cited 2015 Jun 16]. Report No.: NIAAA Publications Distribution Center; 2005. Available at: http://pubs.niaaa.nih.gov/publications/practitioner/cliniciansguide2005/guide.pdf,
   Google Scholar
• Groenwold RHH, Donders ART, Roes KCB, Harrell FE, Moons KGM. Dealing with missing outcome data in randomized trials and observational studies. Am J Epidemiol 2011 Dec 23;kwr302.
   Google Scholar
• Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, et al. Association of cigarette smoking With HIV prognosis among women in the HAART era: a report from the Women’s Interagency HIV Study. Am J Public Health 2006 Jun 1;96:1060–1065.
   Web of Science ®Google Scholar
• Rasbach DA, Desruisseau AJ, Kipp AM, Stinnette S, Kheshti A, Shepherd BE, et al. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care 2013;25:109–117.
   PubMed Web of Science ®Google Scholar